1 / 32

Cardiac Intervention in the Elderly

Cardiac Intervention in the Elderly. Cardiac Interventions. Coronary Artery Bypass Grafting (CABG) Percutaneous Transluminal Coronary Angioplasty (PTCA) ± stenting Valve surgery Radio-frequency Ablation Automatic Implantable Cardiac Defibrillators (AICDs). Ischaemic Heart Disease.

aric
Download Presentation

Cardiac Intervention in the Elderly

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cardiac Intervention in the Elderly

  2. Cardiac Interventions • Coronary Artery Bypass Grafting (CABG) • Percutaneous Transluminal Coronary Angioplasty (PTCA) ± stenting • Valve surgery • Radio-frequency Ablation • Automatic Implantable Cardiac Defibrillators (AICDs)

  3. Ischaemic Heart Disease • Largest single cause of death in developed world • Medical therapy • CABG (Favaloro in 1969) • PTCA (Gruentzig in 1977) • Coronary stents (Sigwart in 1989)

  4. CABG • 600 000/year in the USA Many trials selective/unrepresentative: • Males under 65 years old • Pre- Aspirin/Beta-blocker/ACE-I/Statin era • Saphenous vein grafts only

  5. CABG - Mortality Mortality (in-hospital) 1.3% Predictors: • AGE • Co-morbidity • Pre-operative LV function • Surgical parameters • IABP requirement

  6. CABG – MortalityNNECDSG SCORE • Age + Gender • LV Ejection Fraction • Urgency of Surgery • Previous CABG • PVD, Diabetes, Renal Failure, COAD • Body Habitus

  7. NNECDSG score Each point = 0.2 – 2 % rise in mortality

  8. CABG – 30 day Mortality

  9. CVA 3% Prior neurological disease IABP use Diabetes Hypertension Unstable angina Increased age Prox. aortic atheroma Drop in intellect 3% Excess alcohol consumption Arrhythmias Hypertension Previous CABG Peripheral vascular disease Congestive heart failure Increased age CABG – Neurological risks

  10. CABG – MorbidityRenal failure • 8 % of all patients • 1 % require dialysis (1.2 % of > 70 years) Major predictor of mortality • 18 % of patients die • 66% of dialysis patients die Risk factors • Advanced age, CCF, re-do surgery, diabetes

  11. CABG – MorbidityMediastinitis • Deep sternal wound infection • 1% to 4% of patients • Mortality of 25% • Predicted by: • Obesity • Re-do surgery • Use of both IMA’s at surgery • Diabetes mellitus

  12. Survival after CABGCABG vs. Medical Rx Mortality: @ 5 years: 10.2 % (CABG) vs. 15.8 % (medical) @ 10 years: 26.4 % (CABG) vs. 30.5 % (medical) Greatest benefit: • Left main stem or equivalent • Proximal LAD involvement

  13. Survival after CABGProximal LAD disease • Relative risk reduction for CABG compared with medical treatment • 42 % @ 5 years • 22 % @ 10 years • Benefit increased if LV impaired

  14. PTCA  stent • Most trials performed before: • Stents • Clopidogrel • IIb/IIIa platelet inhibitors • 447 000 procedures/year in USA (1997)

  15. PTCA  stent • Procedural success now 99.5% (76% in 1986) • Mortality • 0.91% (UK values) • 0 % (stents) • 1.2% (stents in diabetic patients) • Early repeat procedure (<7 months after 1st) • 23.3 % with POBA • 13.5 % with stents

  16. PTCA (no stent)Mortality/morbidity 10 year follow-up: • Q-wave MI 3.9% • non Q-wave MI 11.3% • Death 23.1 % • CABG 32.7 % • Repeat procedure 38% • Recurrent angina 56.3 % • Risk factors: • Extent of disease • Diabetes • Hypertension • Previous MI • Male • Age >70 (mortality)

  17. PTCA + stentingMortality/morbidity Follow – up data is over shorter period Most data is pre - ticlopidine/clopidogrel • Death rate @ 1 year 0.7 – 1.2% • Target lesion re-intervention 15% (1yr) • Cardiac event free survival 78% (1yr) Outcomes similar for single vs. multivessel

  18. PTCA + stentingMortality/morbidity Influence of ticlopidine • MACE level dropped from: • 24.1% to 9.0 % (in hospital) • 47% to 33% (2 years)

  19. PTCA  stentingInfluence of age Study from 1980 –1996

  20. PTCA  stentingInfluence of age

  21. CABG or PTCA? • Data pre-stent / clopidogrel / IIb/IIIa inhibitors • BARI trial:Lower mortality with CABG vs. PTCA • Diabetic patients do better with CABG • Non-diabetic patients – No difference • QALY/activity/employment/costs equivalent at 5 years • Recurrence of angina higher in PTCA • 21% vs 15% @ 5 years

  22. Age > 80 years MVR AVR Valve surgery in > 80 yrs age • High rate of co-morbidity • 40-60% IHD  15-25% COAD • 5-25% CVA 20-50% Hypertension

  23. Age > 80 years MVR AVR Valve surgery in > 80 yrs age Risk score EF: 30-50% +2 EF <30% +5 Re-operation +2 Valve & CABG +2

  24. Valve surgery in > 80 yrs ageAppropriateness of surgery • AVR for severe aortic stenosis +++ • MVR for severe mitral regurgitation ++ • AVR for moderate AS during CABG ++ • MV repair for moderate MR at CABG + • Balloon valvuloplasty for MS + • MVR for moderate MR during CABG 0 • AVR + MVR 0 • Balloon valvuloplasty of aortic valve 0

  25. Symtomatic Aortic Stenosis in the > 80 Year Old

  26. Radio-frequency ablation • Introduced in the 1980’s • Treatment of choice in symptomatic SVT’s • AVNRT • AVRT (i.e. WPW) • Atrial flutter • NO PROGNOSTIC ADVANTAGE

  27. RFA Statistics • Mortality 0.3% • Major complication 3% • Success 85 – 100% (95%) • Recurrence 2 – 21%

  28. RFA in the elderly • Little data • Most common procedure is AVJ (node) ablation for atrial fibrillation + PPM • Age not a predictor of success/complication • Structural heart disease • Multiple accessory pathways • Heart disease • Low ejection fraction • AVJ ablation Complications Death

  29. AICD’s • Undoubted prognostic benefit • Procedural mortality 0.5 – 0.8 % • Primary prevention • Secondary prevention

  30. AICD’s –Primary Prevention • Previous MI and all of the following: • Non-sustained VT on Holter (24 hour ECG) • Inducible VT at EPS • LV dysfunction • EF < 35% • NYHA I – III • Familial cardiac condition with risk of sudden death (long QT, HOCM etc.)

  31. AICD’s – secondary prevention • Patients who present, in the absence of a treatable cause, with: • Cardiac arrest due to VT or VF • Sustained VT causing syncope or significant haemodynamic compromise • Sustained VT without haemodynamic compromise + EF < 35% + NYHA I - III

  32. Conclusions • Age is a significant risk factor in most cardiac interventions, but does not preclude intervention • Co-morbidity is a major factor in deciding appropriateness of intervention • AVR is well worthwhile in isolated AS • Treat the person, not the birth date!

More Related